Why Insmed (INSM) Stock Is Soaring Today

NEW YORK (TheStreet) -- Insmed  (INSM) soared Wednesday after the FDA granted Breakthrough Therapy Designation for Arikayce, the biotech company's only drug candidate.

Arikayce treats adults with nontuberculous mycobacterial (NTM) lung disease who are treatment refractory. The FDA's designation should accelerate Arikayce's development and review. The FDA based its designation on positive data from the company's Phase 2 clinical trial, as well as an unfulfilled need for NTM lung disease treatments.

Insmed now plans to meet with the FDA to talk about the regulatory pathway for Arikayce, which is also being tested as a possible treatment for pseudomonas lung infections patients with cystic fibrosis and non-cystic fibrosis.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 39.43% to $17.38 at 11:49 a.m.

INSM Price Chart

INSM Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

North Korea Gives Wall Street Rude Awakening After Labor Day Break

Dow Tanks, Fear Gauge Spikes as United Tech Slumps, North Korea Rattles Nerves

North Korea Threat Roars Back Into Focus and Wall Street Retreats

Stock Futures Decline Amid Rising North Korea Tensions

Health Sector Down As Report of Industry Price Collusion Surfaces